Publication Name	World Journal of Hepatology
Manuscript ID	13661
Country	United Kingdom

Received	2014-08-29 10:47
Peer-Review Started	2014-08-31 18:21
To Make the First Decision	2014-11-27 12:12
Return for Revision	2014-12-04 16:04
Revised	2015-01-12 18:49
Second Decision	2015-01-28 12:03
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-02-09 09:38
Articles in Press	2015-02-09 09:38
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-05-01 16:47
Publish the Manuscript Online	2015-05-19 17:28

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Virology
Manuscript Type	Review
Article Title	Current and future antiviral drug therapies of hepatitis B chronic infection
Manuscript Source	Invited Manuscript
All Author List	Lemonica Koumbi
Funding Agency and Grant Number
Corresponding Author	Lemonica Koumbi, Research Fellow, Hepatology and Gastroenterology Section, Department of Medicine, Imperial College London, St. Mary’s Campus, Norfolk Place, London W2 1PG, United Kingdom. lemonica.koumbi@gmail.com
Key Words	Nucleos(t)ide analogues; Interferon-α; Drug resistance; Immunotherapy; Hepatitis B therapy
Core Tip	Despite significant improvement in the management of chronic hepatitis B virus (HBV) it remains a public health problem. Current therapeutic regimens include pegylated-interferon (IFN)-α and nucleos(t)ide analogues (NAs). Both treatments do not eradicate the virus and have numerous limitations. IFN therapy is of finite duration and has low response rates while long-term NA therapies have a high risk of drug resistance. The development of new therapeutic approaches is imperative. This review brings together current treatments and the ongoing research efforts on evaluating potential therapeutic strategies that target the suppression of HBV replication the restoration of the weak immune responses against HBV.
Publish Date	2015-05-19 17:28
Citation	Koumbi L. Current and future antiviral drug therapies of hepatitis B chronic infection. World J Hepatol 2015; 7(8): 1030-1040
URL	http://www.wjgnet.com/1948-5182/full/v7/i8/1030.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i8.1030

Full Article (PDF)	WJH-7-1030.pdf
Full Article (Word)	WJH-7-1030.doc
Manuscript File	13661-Review.docx
Answering Reviewers	13661-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	13661-Conflict-of-interest statement.pdf
Copyright License Agreement	13661-Copyright assignment.pdf
Peer-review Report	13661-Peer-review(s).pdf
Scientific Misconduct Check	13661-Scientific misconduct check.pdf
Scientific Editor Work List	13661-Scientific editor work list.pdf